Abstract
Oncolytic Virus therapy, including HSV-1 and adenovirus, is a new type of tumour immunotherapy that uses specific viruses to directly kill tumour cells or to induce the body's intrinsic and acquired immunity to generate anti-tumour immune responses. In addition, Oncolytic Virus is capable of recruiting immune cells to improve the tumour microenvironment, so the development of The clinical significance of oncolytic virus therapy lies in its potential to enhance the efficacy of other immunotherapeutic approaches. However, the delivery of Oncolytic Virus in current clinical trials has huge defects, which greatly limits the benefits of Oncolytic Virus and even produces certain side effects. Therefore, this review discusses the definition and mechanism of Oncolytic Virus and focuses on the defects in Oncolytic Virus delivery, such as systemic delivery and intratumoural delivery. Further, this review also summarizes some improvement strategies against the challenges of intratumoural heterogeneity and vascular complexity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
